{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07805954\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"RASolute 309","nct_id":"NCT07805954","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rasolute-309-nct07805954. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RASolute 309","arms":[{"description":"combination of study drugs","label":"Arm A: daraxonrasib + zoldonrasib","type":"EXPERIMENTAL"},{"description":"chemotherapy","label":"Arm B: gemcitabine and nab-paclitaxel","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma"],"enrollment":{"count":400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"daraxonrasib","otherNames":[],"type":"DRUG"},{"name":"gemcitabine","otherNames":[],"type":"DRUG"},{"name":"nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"zoldonrasib","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"Revolution Medicines, Inc.","official_title":"A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 4 years"},{"measure":"Overall survival (OS)","timeFrame":"Up to approximately 4 years"}],"references":[],"start_date":{"date":"2026-08-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT07805954"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rasolute-309-nct07805954"}